- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02161965
Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation (VICTORIA)
The VICTORIA Study (Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation) Comparison Anti-vitamin K Versus Anti-Xa.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Long term oral anticoagulant treatment (> 12 month) is mainly indicated for atrial fibrillation, prosthetic valves and conditions with high risk for recurrent or deep venous thrombosis. For more than 60 years, vitamin K antagonists have been the only oral anticoagulant drugs available to prevent thrombus formation. The use of vitamin K antagonists is associated to the major constraint of a well-adjusted anticoagulation leading to minor/major risk of life threatening bleeds. They also exhibit other rare side-effects including skin eruption and necrosis, hepatic disorders, alopecia. A less known side effect is an increase in soft tissue calcification, including the cardiac valves and the peripheral arterial system. This side effect is explained by the inhibitory effect of vitamin K antagonists on the central (liver) and peripheral (e.g. vascular) carboxylation cycle synthesis of several vitamin K-dependant calcification inhibiting factors, such as the matrix gamma-carboxyglutamate protein, osteocalcin or Gas6 (1). The active form of gamma-carboxyglutamate protein is now identified as a potent local tissue inhibitor of vascular calcification. The calcifying effect of a decrease in gamma-carboxyglutamate protein or the ratio of carboxylated (i.e. active) /uncarboxylated (i.e. inactive) forms of gamma-carboxyglutamate protein have been reported in various acquired metabolic diseases such as chronic renal insufficiency, aging and of genetic origin (e.g. Cutis Laxa, Keutel syndrome,…) (2, 3) as well as in mouse gamma-carboxyglutamate protein -/- models (4). Furthermore, administration of warfarin in rats is a well-known pharmacological model to induce a vascular calcification within 2-4 weeks with an increase in systolic and pulse arterial blood pressure (5).
Vascular calcification is an independent risk factor for cardiovascular morbi-mortality and it is well-demonstrated that an increase in coronary calcium, as measured by the scan Agatston score, is independently linked to a higher risk for events (6, 7). The lower limb mediacalcosis (i.e. Monckeberg disease) is also a risk factor for limb amputation and calcification (8) of the atheromatous plaque represents a risk factor for plaque instability and rupture (9). The pathophysiological mechanisms linking the dystrophic calcification process to morbi-mortality are still unclear. Calcium deposit within the arterial intimal layer is generally associated to atherosclerosis with an increased risk for plaque rupture whereas deposit of calcium within the medial layer of the peripheral arteries (i.e. mediacalcosis) is rather responsible for an increased arterial stiffness and the development of arterial hypertension (10). Recent data from the investigators laboratory have showed site heterogeneity assessed by scan scoring in the calcifying process in the general population and also in a genetically-determined calcifying disease (i.e the pseudoxantoma elasticum).
Two recently published studies have pointed out a link between the use of vitamin K antagonists and an enhanced coronary (11) and extra-coronary (6) calcifications. Although the conclusions of these studies remains limited by a cross-sectional and retrospective design, a small number of patients and a large range of exposure to vitamin K antagonists (from 6 to 143 months - mean 46) they questioned a potential deleterious effect on the peripheral vasculature mainly for the long term use of non-vitamin K antagonists anticoagulants. One prospective controlled study in post-menopaused woman has demonstrated a long-term beneficial effect only of a supplement containing vitamins K1 and D on the elastic properties of the carotid artery (12). Therefore, in the present study, the investigators propose to determine the structural (i.e. calcification) and functional (i.e. stiffness) impact of the anti-Xa inhibitor rivaroxaban compared to vitamin K antagonists on the arterial structure in a longitudinal, prospective comparative study.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Angers, France, 49933
- University Hospital Angers
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patient aged > 18 years
- Female patient capable of bearing children with highly effective methods of birth control
- Creatinine clearance > 30 ml/min
- Normal hepatic function based on hepatic enzymes
- Treated for atrial fibrillation according a score superior at 1
- Treatment duration 12 months according to the actual recommendations
- Treated by vitamine K antagonist less than 2 months before entering the study
- Patient willing to participate with a signed informed consent
- Patient covered by a healthcare insurance
Exclusion Criteria:
- Patient has any clinical condition which does not allow initiation of long-term including all contraindications such as hypersensitivity to active ingredient or other excipients, clinically relevant acute bleedings and all other risk circumstances according to Summary of Medicinal Product in which all warnings and preventive measures and precautions are described and have to be kept.
- Patients had a previous coronary stent implantation
- Creatinine clairance <30 mL)
- Liver disease with coagulopathy or other bleeding disorders including cirrhotic patients with Child Pugh
- Hyperthryroidism
- Hypercalcemia
- Hyperphosphatemia
- Acute gastrointestinal diseases
- Mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study
- Patient is unwilling or unable to give informed consent
- Patient is unlikely to comply with protocol, e.g. uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study
- Participation in a parallel interventional clinical trial
- Patient has been committed to an institution by legal or regulatory order
- Pregnant or lactating women
- Female patient capable of bearing children without highly effective methods of birth control
- Patient with history of myocardial infarction and/or coronary disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rivaroxaban
Rivaroxaban (oral tablet) for patients with atrial fibrillation: 20 mg once daily for patients with GFR > 49 ml per minute and 15 mg rivaroxaban once daily for patients with GFR of 15 to 49 ml. Rivaroxaban (oral tablet) for patients with pulmonary embolism: 2 x a day 15 mg at day 1-21 and 1x 20 mg from day 22 ongoing |
20mg or 15mg
Other Names:
|
Active Comparator: vitamin K antagonists
Adjusted dose of warfarin or fluindione (oral tablet) titrated according to target international normalized ratio with a target range 2.0 to 3.0.
|
Other Names:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Calcification score measured by CT scan
Time Frame: 2 months
|
Rate of coronary and lower Limb calcifications between oral inhibitor of Xa activity and vitamin K antagonists
|
2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Arterial stiffness measured by ultrasounds
Time Frame: 3 months
|
Compare the impact of an oral anti-Xa and vitamin K antagonist on the arterial stifffness.
|
3 months
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Dosage of circulating anti-calcifying factors and extra-cellular matrix remodelling
Time Frame: 2 months
|
2 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Georges LEFTHERIOTIS, MD, PhD, University hospital, Angers, FRANCE
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Metabolic Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Embolism and Thrombosis
- Arrhythmias, Cardiac
- Calcium Metabolism Disorders
- Embolism
- Atrial Fibrillation
- Thrombosis
- Venous Thrombosis
- Pulmonary Embolism
- Calcinosis
- Vascular Calcification
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protease Inhibitors
- Factor Xa Inhibitors
- Antithrombins
- Serine Proteinase Inhibitors
- Anticoagulants
- Rivaroxaban
- Warfarin
- Fluindione
- Phenindione
Other Study ID Numbers
- 2012-005354-27
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Venous Thrombosis
-
Hospital de Clinicas de Porto AlegreCompletedDeep Venous Thromboses | Deep Venous Thrombosis of Left Leg | Deep Venous Thrombosis of Right Leg | Deep Venous Thrombosis Proximal
-
Merit Medical Systems, Inc.CompletedChronic Venous Thrombosis | Venous Thrombosis Upper Extremity | Venous Thrombosis Upper Extremity Superficial VeinsAustria, Germany, Italy
-
Intermountain Health Care, Inc.TerminatedDeep Vein Thrombosis | Venous Thromboembolism | Deep Venous Thrombosis | Thrombus | Upper Extremity Deep Venous ThrombosisUnited States
-
Policlinico HospitalCompletedCentral Venous Catheter Thrombosis | Intensive Care Unit | Thrombosis, Venous | Central Venous CathetersItaly
-
Johns Hopkins UniversityPatient-Centered Outcomes Research InstituteCompletedVenous Thrombosis (Disorder)United States
-
University of Roma La SapienzaUnknownVenous Thromboembolism | Deep Venous ThrombosisItaly
-
The First Affiliated Hospital of Guangzhou Medical...CompletedDeep Venous Thrombosis
-
Russian Phlebological AssociationRecruitingVenous Insufficiency | Varicose Veins of Lower Limb | Thromboses, VenousRussian Federation
-
Tong ZhuNot yet recruitingDeep Vein Thrombosis | Deep Venous Insufficiency
-
Maastricht University Medical CenterTerminatedRandomized Clinical Trial | Deep-Venous Thrombosis | Deep Venous StentingNetherlands
Clinical Trials on Warfarin
-
University Hospital, BrestCompleted
-
University Hospital, BrestCompletedRecurrent Venous Thromboembolism | Idiopathic Deep Vein ThrombosisFrance
-
University of PadovaCompleted
-
Federal University of São PauloFundação de Amparo à Pesquisa do Estado de São PauloCompletedAtrial FibrillationBrazil
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI); Duke Clinical Research InstituteTerminatedIdiopathic Pulmonary FibrosisUnited States
-
Azienda Ospedaliera Universitaria PoliclinicoCompletedDeep Vein ThrombosisItaly
-
National University Hospital, SingaporeUnknownIndications for Warfarin TherapySingapore, Malaysia
-
University of KarachiAdvanced Education & Research Center; Karachi Institute of Heart DiseasesRecruitingLeft Atrial Appendage Aneurysm | Mitral StenosisPakistan
-
Jonsson Comprehensive Cancer CenterNovartis PharmaceuticalsCompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Massachusetts General HospitalNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Diseases | Cardiovascular Diseases | Cerebrovascular Disorders | Atrial Fibrillation | Arrhythmia | Cerebrovascular Accident | Thrombophlebitis | Cerebral Embolism and Thrombosis